nach oben

Strahlentherapie und Onkologie

Erschienen in:

04.01.2019 | Letter to the Editor

Comment to Impact of postmastectomy radiotherapy on the outcomes of breast cancer patients with T1-2 N1 disease; an individual patient data analysis of three clinical trials

verfasst von: PD Dr. med. Christiane Matuschek, David Krug, Rainer J. Klement, René Baumann

Erschienen in: Strahlentherapie und Onkologie | Ausgabe 4/2019

Einloggen, um Zugang zu erhalten

Excerpt

Abdel-Rahman [1] analyzed the overall survival-rate and disease-free survival of T1-2 N1 breast cancer patients after mastectomy, who were adjuvantly treated with various modern chemotherapeutic drugs (anthracyclines, taxanes) in 3 prospective phase III chemotherapy trials. His analysis suggested no potential benefits of an additional adjuvant postmastectomy radiotherapy (PMRT). The included trials were the BIG 02/98 [6], the BCIRG 001 [7] and the BCIRG-005 [5] trials. The author concludes that in T1-2 N1 breast cancer patients who have received modern chemotherapy drugs PMRT does not provide any benefit for overall and disease-free survival. Prospective studies are necessary. …

Abdel-Rahman O (2018) Impact of postmastectomy radiotherapy on the outcomes of breast cancer patients with T1-2 N1 disease: an individual patient data analysis of three clinical trials. Strahlenther Onkol. https://doi.org/10.1007/s00066-018-1343-x CrossRefPubMed

Abdel-Rahman O, Cheung WY (2018) Impact of smoking history on the outcomes of women with early-stage breast cancer: a secondary analysis of a randomized study. Med Oncol 35:68CrossRefPubMed

Budach W, Bolke E, Kammers K et al (2015) Adjuvant radiation therapy of regional lymph nodes in breast cancer—a meta-analysis of randomized trials- an update. Radiat Oncol 10:258CrossRefPubMedPubMedCentral

Early Breast Cancer Trialists’ Collaborative Group, Mcgale P, Taylor C et al (2014) Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet 383:2127–2135CrossRef

Eiermann W, Pienkowski T, Crown J et al (2011) Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2‑normal, node-positive breast cancer: BCIRG-005 trial. J Clin Oncol 29:3877–3884CrossRefPubMed

Fernandez-Cuesta L, Oakman C, Falagan-Lotsch P et al (2012) Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial. Breast Cancer Res 14:R70CrossRefPubMedPubMedCentral

Mackey JR, Martin M, Pienkowski T et al (2013) Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial. Lancet Oncol 14:72–80CrossRefPubMed

Mcbride A, Allen P, Woodward W et al (2014) Locoregional recurrence risk for patients with T1,2 breast cancer with 1–3 positive lymph nodes treated with mastectomy and systemic treatment. Int J Radiat Oncol Biol Phys 89:392–398CrossRefPubMed

Poortmans PM, Collette S, Kirkove C et al (2015) Internal mammary and medial supraclavicular irradiation in breast cancer. N Engl J Med 373:317–327CrossRefPubMed

10.

Whelan TJ, Olivotto IA, Parulekar WR et al (2015) Regional nodal irradiation in early-stage breast cancer. N Engl J Med 373:307–316CrossRefPubMedPubMedCentral

Titel: Comment to Impact of postmastectomy radiotherapy on the outcomes of breast cancer patients with T1-2 N1 disease; an individual patient data analysis of three clinical trials
verfasst von: PD Dr. med. Christiane Matuschek
David Krug
Rainer J. Klement
René Baumann
Publikationsdatum: 04.01.2019
Verlag: Springer Berlin Heidelberg
Erschienen in: Strahlentherapie und Onkologie / Ausgabe 4/2019
Print ISSN: 0179-7158
Elektronische ISSN: 1439-099X
DOI: https://doi.org/10.1007/s00066-018-1411-2

Neu im Fachgebiet Onkologie

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Comment to Impact of postmastectomy radiotherapy on the outcomes of breast cancer patients with T1-2 N1 disease; an individual patient data analysis of three clinical trials

Excerpt

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2019

Comparison of treatment plans for a high-field MRI-linac and a conventional linac for esophageal cancer

Reply to the letter to the editor “Comment to ‘Impact of postmastectomy radiotherapy on the outcomes of breast cancer patients with T1-2 N1 disease; an individual patient data analysis of three clinical trials’”

Radiotherapy of epicondylitis humeri

Pattern of care of adjuvant radiotherapy in male breast cancer patients in clinical practice: an observational study

A comparison of a brachytherapy and an external beam radiotherapy boost in breast-conserving therapy for breast cancer: local and any recurrences

Low-dose radiotherapy: Mayday, mayday. We’ve been hit!

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie